KELONG bio compete for market share agent overseas IVD giant products www.xinkebiao.com.cn

KELONG biological agent for market share overseas IVD products giant hot column capital flows thousands of thousands of stocks the latest Rating Rating diagnosis simulated trading client sina finance App: Live on-line blogger to tutor the purchase of new shares: the stock market is the most simple way to pick up the money – after each intern reporter Wu Fan as a domestic in vitro diagnostic (IVD) industry leader enterprise, KELONG bio (002022, SZ), to expand the domestic market at the same time, is also seeking cooperation with foreign professional companies the opportunity. In September 27th, KELONG biological announcement that with the Spanish walfen group (WerfenGroup.) subsidiary BiokitS.A. company signed a "strategic cooperation memorandum". KELONG bio will be the sole agent in the country’s exclusive Biokit S.A.’s desktop fully automated chemiluminescence immunoassay system, and jointly develop new testing projects Bio-Flash. KELONG biological said, this and Biokit S.A.’s strategy to work together, will further expand the company’s international cooperation, but also to further consolidate the company’s leading position in the field of in vitro diagnostics. Daily economic news reporter noted that the cooperation between KELONG and foreign giants with the same industry reflects the embarrassment of domestic IVD companies, the market share is not high. It is reported that foreign giants in hand and agent products, KELONG’s main business is engaged in biological immune in vitro clinical diagnostic reagents, clinical diagnostic reagents in vitro chemical research, production and sales, which, in vitro diagnostic products, also known as IVD (In-Vitro Diagnostics), refers to the detection of access to clinical diagnostic information products and services based on the human body the blood tissue and secretion in the human body. For the cooperation with the BiokitS.A. company, KELONG biological said the cooperation between the two sides will give full play to the advantages of the company in the IVD professional fields of technology, market and channels, in a comprehensive domestic sole agent Biokit S.A.’s Bio-Flash desktop automatic chemiluminescence immunoassay system, and jointly develop new test items; automatic chemiluminescent immunoassay and to introduce high quality Chinese IVD market analysis products. In fact, BiokitS.A. is a root of the in vitro diagnostics industry company. Public information, BiokitS.A. was founded in 1973, is engaged in in vitro diagnosis of international developers and manufacturers, its core competitiveness is the development and production of immune products. Its parent company is an in vitro diagnostic "time-honored" solutions and create a pioneer company walfen group. The latter was founded in 1966, headquartered in Barcelona, spain. It is reported that, at present, the world’s top ten IVD companies are BiokitS.A customers, BiokitS.A annual output of more than 120 million tests, the distribution of the world’s more than and 100 countries and 8000 medical institutions. Golden State Securities research reported in September 28th, the introduction of high quality chemical luminous products, create a competitive theory相关的主题文章: